8-K: Senti Bio's SENTI-202 Shows Positive Preliminary Clinical Results in Relapsed/Refractory AML

Senti Biosciences reports positive preliminary Phase 1 clinical trial data for SENTI-202, a novel CAR-NK cell therapy for relapsed/refractory AML, demonstrating promising efficacy and a manageable safety profile.

Summary

• Senti Biosciences announced positive preliminary data from its Phase 1 clinical trial of SENTI-202 for relapsed/refractory AML.
• The data, presented at the AACR Annual Meeting 2025, showed promising efficacy and a manageable safety profile.
• The study evaluated two dose levels (1 or 1.5 x 10^9 CAR NK cells/dose) and two schedules (3 or 5 doses) of SENTI-202.
• The preliminary recommended Phase 2 dose (RP2D) was identified as 1.5 x 10^9 CAR NK cells administered on Days 0, 7, and 14 in 28-day cycles.
• 5 of 7 evaluable patients achieved an Overall Response Rate (ORR), and 4 of 7 achieved a composite Complete Remission (cCR).
• 4 of 4 cCR patients were Measurable Residual Disease (MRD) negative.
• All cCR patients continue in remission with the longest follow-up being 8+ months.
• SENTI-202 was detected in all treated patients, with a PK profile consistent with other allogeneic CAR NK cell therapies.
• The company held cash and cash equivalents of approximately $33.8 million as of March 31, 2025.
• Research and development expenses were $9.3 million for the three months ended March 31, 2025.
• Net loss was $14.1 million, or $1.41 per basic and diluted share, for the quarter ended March 31, 2025.

Sentiment

Score: 8

Explanation: The document presents positive preliminary clinical data, a manageable safety profile, and encouraging MRD results. While there are risks and uncertainties associated with clinical development, the overall tone is optimistic.

Positives

• SENTI-202 shows promising preliminary efficacy in treating relapsed/refractory AML.
• The therapy was well-tolerated in the Phase 1 trial.
• The trial identified a preliminary recommended Phase 2 dose (RP2D).
• The treatment led to a decrease in leukemia stem cell (LSC) frequencies and maintained or increased healthy hematopoietic stem and progenitor cell (HSPC) frequencies in patients achieving cCR.
• 4 of 4 cCR patients were MRD(Measurable Residual Disease Negative).
• All cCR patients continue in remission with the longest follow-up being 8+ months.

Negatives

• The results are preliminary and based on a small number of patients.
• The company reported a net loss of $14.1 million for the quarter ended March 31, 2025.
• Enrollment has been stopped for SN301A Investigator Sponsored Trial due to dose limiting toxicities.

Risks

• The forward-looking statements are subject to various risks and uncertainties, including those related to clinical trial start-up, studies, patient enrollment, and GMP manufacturing activities.
• The company's dependence on third parties for clinical trials and manufacturing poses a risk.
• Macroeconomic and geopolitical events, increasing rates of inflation, and rising interest rates could impact business operations.
• There is a risk related to the timing and utilization of the grant from CIRM.
• The success of future research and development efforts is uncertain.

Future Outlook

Senti Bio is continuing to enroll patients in the Phase 1 study of SENTI-202 to confirm the preliminary RP2D, followed by disease-specific expansion cohorts. The company is also evaluating next steps with SENTI-301A/SN301A as part of ongoing pipeline prioritization.

Management Comments

• Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences commented, 'Senti was founded on engineering Logic Gated cell therapies with the enhanced ability to selectively kill cancer cells and protect healthy cells for cancer indications not addressable by existing drugs.'
• Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio summarized, 'Based on our clinical, correlative and preclinical data, we believe SENTI-202 has the potential to provide a safe and effective treatment option for AML.'
• Stephen A. Strickland, Jr., MD, MSCI, Director, Leukemia Research for Sarah Cannon Research Institute, added, 'While preliminary, the results demonstrated by SENTI-202 to date continue to be encouraging.'

Industry Context

The announcement is significant in the context of the CAR-NK cell therapy field, as SENTI-202 utilizes a novel Logic Gated approach to enhance precision and safety. This approach aims to overcome limitations of traditional CAR-T and CAR-NK therapies by selectively targeting cancer cells while sparing healthy cells.

Comparison to Industry Standards

• The reported ORR of 71% and cCR rate of 57% in relapsed/refractory AML patients are promising compared to current standard of care responses, which typically show CR rates of 15-25% and CR/CRh rates of 20-33%.
• Companies like Fate Therapeutics and Nkarta Therapeutics are also developing allogeneic NK cell therapies, but Senti Bio's Logic Gated approach differentiates SENTI-202.
• The ability to achieve MRDstatus in all cCR patients is a positive indicator of deep and durable remission, which is a key goal in AML treatment.
• The longest follow up of 8+ months is still relatively early, but the ongoing remissions are encouraging.

Stakeholder Impact

• Positive clinical data could lead to increased shareholder value.
• Successful development of SENTI-202 could provide a new treatment option for AML patients.
• Employees may benefit from the company's progress and potential growth.
• The company's partnerships and collaborations could be strengthened by the positive results.

Next Steps

• Continue enrollment in the Phase 1 study of SENTI-202 to confirm the preliminary RP2D.
• Proceed with disease-specific expansion cohorts in the Phase 1 study.
• Evaluate next steps with SENTI-301A/SN301A as part of ongoing pipeline prioritization.
• Present additional data on SENTI-202 in two additional posters during the AACR meeting.

Key Dates

Keywords

SENTI-202, AML, CAR-NK, Senti Biosciences, Clinical Trial, Gene Circuit, Hematologic Malignancies, AACR, MRD, R/R AML